<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456766</url>
  </required_header>
  <id_info>
    <org_study_id>TG1310FT</org_study_id>
    <nct_id>NCT02456766</nct_id>
  </id_info>
  <brief_title>Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis</brief_title>
  <official_title>A Multicenter Clinical Study on the Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for the Diagnosis of Hepatic Steatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuxi Hisky Medical Technology Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>No.85 Hospital, Changning, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Academy of Medical Sciences &amp;Sichuan Provincial People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuxi Hisky Medical Technology Co Ltd</source>
  <brief_summary>
    <textblock>
      This will be a multi-center, prospective, controlled study. It is expected that about 240
      subjects from 10 study centers will be enrolled, and 224 effective subjects will be
      statistically analyzed in the end, in which 56 effective subjects with stage F0 (25%), 56
      effective subjects with stage F1 (25%), 56 effective subjects with stage F2 (25%), 56
      effective subjects with stage F3 (25%). By comparison of the result of FibroTouch examination
      with that of liver biopsy, their specificities, sensitivities and accuracies for diagnosis of
      liver steatosis will be identified.

      The patients with liver diseases who need to have a liver biopsy in hospital and meet all of
      the inclusion criteria and none of the exclusion criteria, may participate in this study.
      Within two weeks of FibroTouch examination, subjects are required to have qualified
      histological specimens of liver biopsy for comparation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The coincidence for diagnosis of hepatic steatosis between fat attenuation parameter (FAP) of FibroTouch and liver biopsy by ROC analysis</measure>
    <time_frame>Within two weeks of FibroTouch examination</time_frame>
    <description>Performance of fat attenuation parameter (FAP, dB/m) of FibroTouch will be assessed using ROC analysis for the detection of hepatic steatosis stage F0 (&lt;5%), stage F1 (5%-33%), stage F2 (34%-66%), and stage F3 (2&gt;66%) using liver biopsy as the reference.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Hepatic Steatosis</condition>
  <condition>Liver Steatosis</condition>
  <arm_group>
    <arm_group_label>F0</arm_group_label>
    <description>Liver Steatosis Grade: &lt;5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F1</arm_group_label>
    <description>Liver Steatosis Grade: 5-33%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F2</arm_group_label>
    <description>Liver Steatosis Grade: 34-66%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F3</arm_group_label>
    <description>Liver Steatosis Grade: &gt; 66%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroTouch</intervention_name>
    <arm_group_label>F0</arm_group_label>
    <arm_group_label>F1</arm_group_label>
    <arm_group_label>F2</arm_group_label>
    <arm_group_label>F3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Biopsy</intervention_name>
    <arm_group_label>F0</arm_group_label>
    <arm_group_label>F1</arm_group_label>
    <arm_group_label>F2</arm_group_label>
    <arm_group_label>F3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver Biospy Specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects with liver diseases who need to have a liver biopsy in hospital and meet all
        of the inclusion criteria and none of the exclusion criteria, may participate in this
        study. Within two weeks of FibroTouch examination, subjects are required to have qualified
        histological specimens of liver biopsy for comparation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject at the age of 18 to 65 years, non-limited gender.

          -  Within two weeks of FibroTouch examination, qualified histological specimens of liver
             biopsy are required. Using the liver biopsy needle of 16G or 14CT, puncture and remove
             more than 2.0 centimeters long liver tissue (including at least 11 portal areas, no
             less than 6 complete portal areas and the minimum length of specimen should be more
             than 1.0 centimeter).

          -  Willing and able to abide by all principles and complete all study procedures.

          -  Willing and can provide written informed consent form by patient or patient's legal
             guardian.

        Exclusion Criteria:

          -  Subject with active or suspected cancer or history of malignant tumor by evidence
             within 5 years before enrolling. And the subject who has the liver malignant tumors
             injury cannot participate in this study.

          -  There is evidence that the subject has a history of alcohol overdoses* or drug abuse.
             Definition of alcohol overdoses: 40 gram (g)/day for male and 40 g/day for female.
             Alcohol intake (g) = the volume of drinking (ml) × alcohol percentage (%, v/v) × 0.8
             (g/ml); 1g alcohol is the equal of 25-40 ml of beer, 8-10ml of Chinese rice wine,
             5-12ml of (grape) wine, 3-7ml of health care liquor or Chinese spirits.

          -  Subject with alcoholic liver disease and hepatitis C.

          -  Pregnant or nursing woman, and subject with a pregnant plan and is unwilling to take
             contraceptive measures during this study.

          -  Subject with history of organ transplantation or has functional grafts (except for the
             cornea or hair graft).

          -  Subject with non-healing wound on the right upper abdomen at this moment.

          -  In the investigator's opinion, the subject is unsuitable to participate in the study
             as he or she has a history of serious illness, or other evidence shown that the
             subject has any other serious illness.

          -  Subject who participates in other clinical trial at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lungen LU, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng LU, Bachelor</last_name>
    <phone>+86-10-62701872</phone>
    <email>lupeng@fibrotouch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo WANG, Bachelor</last_name>
    <phone>+86-10-62701872</phone>
    <email>wangbo@fibrotouch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sichuan Academy of Medical Sciences &amp;Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangping LI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjian ZHOU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junping SHI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongfeng YANG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing XIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai 85 Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingchun FU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lungen LU, MD</last_name>
      <email>lungenlu1965@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangao FAN, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FibroTouch</keyword>
  <keyword>acoustic attenuation parameter</keyword>
  <keyword>liver biopsy</keyword>
  <keyword>hepatic steatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

